Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Madrigal Pharmaceuticals Inc (MDGL)

Madrigal Pharmaceuticals Inc (MDGL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,286,686
  • Shares Outstanding, K 22,711
  • Annual Sales, $ 180,130 K
  • Annual Income, $ -465,890 K
  • EBIT $ -307 M
  • EBITDA $ -305 M
  • 60-Month Beta -1.00
  • Price/Sales 14.91
  • Price/Cash Flow N/A
  • Price/Book 18.33

Options Overview Details

View History
  • Implied Volatility 44.26% (-1.93%)
  • Historical Volatility 42.50%
  • IV Percentile 3%
  • IV Rank 11.00%
  • IV High 82.86% on 04/08/25
  • IV Low 39.49% on 08/15/25
  • Expected Move (DTE 29) 40.72 (8.18%)
  • Put/Call Vol Ratio 0.61
  • Today's Volume 106
  • Volume Avg (30-Day) 569
  • Put/Call OI Ratio 0.53
  • Today's Open Interest 9,732
  • Open Int (30-Day) 14,893
  • Expected Range 457.33 to 538.76

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.01
  • Number of Estimates 8
  • High Estimate 1.96
  • Low Estimate -0.98
  • Prior Year -2.71
  • Growth Rate Est. (year over year) +99.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
483.55 +3.00%
on 01/20/26
615.00 -19.02%
on 12/24/25
-104.79 (-17.38%)
since 12/22/25
3-Month
393.61 +26.53%
on 10/29/25
615.00 -19.02%
on 12/24/25
+82.09 (+19.74%)
since 10/22/25
52-Week
265.00 +87.94%
on 05/27/25
615.00 -19.02%
on 12/24/25
+173.33 (+53.38%)
since 01/22/25

Most Recent Stories

More News
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated...

MDGL : 498.04 (+0.22%)
Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated...

MDGL : 498.04 (+0.22%)
Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor

Agreement expands Madrigal’s pipeline and strengthens its leadership in pioneering MASH therapies DGAT-2 inhibition represents a complementary mechanism of action with Rezdiffra ® (resmetirom)...

MDGL : 498.04 (+0.22%)
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated...

MDGL : 498.04 (+0.22%)
Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

CONSHOHOCKEN, Pa., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the J.P. Morgan Annual Healthcare Conference on...

MDGL : 498.04 (+0.22%)
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated...

MDGL : 498.04 (+0.22%)
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated...

MDGL : 498.04 (+0.22%)
Metabolic Reset: Cell Therapies and Novel Drugs Reshape Chronic Disease Market

VANCOUVER – Baystreet.ca News Commentary – The metabolic disorder therapeutics market projects growth to $120.7 billion by 2030 as biotechnology firms pioneer organ-level treatments addressing diabetes,...

AVAI : 0.7391 (-1.26%)
TNDM : 20.59 (-0.72%)
CRNX : 54.95 (-0.83%)
MDGL : 498.04 (+0.22%)
ALT : 5.38 (+16.45%)
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

CONSHOHOCKEN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences:...

MDGL : 498.04 (+0.22%)
Madrigal Presents New Data Demonstrating Rezdiffra® (resmetirom) Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated MASH Cirrhosis

Rezdiffra ® treatment significantly improved liver stiffness, fibrosis biomarkers, and markers of clinically significant portal hypertension risk in patients with compensated MASH cirrhosis Rezdiffra...

MDGL : 498.04 (+0.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-' agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia...

See More

Key Turning Points

3rd Resistance Point 516.01
2nd Resistance Point 510.01
1st Resistance Point 504.02
Last Price 498.04
1st Support Level 492.03
2nd Support Level 486.03
3rd Support Level 480.04

See More

52-Week High 615.00
Last Price 498.04
Fibonacci 61.8% 481.30
Fibonacci 50% 440.00
Fibonacci 38.2% 398.70
52-Week Low 265.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar